Eudra GMP - Public Layout

MIA | GMP | API REG | WDA | GDP | Sites

Help

Wed 11 Nov 2026 04:45:57 BST

GMP Compliance Menu

GMP Certificates

Non-Compliance Report

The Certificate has been withdrawn, withdrawn date is : 2026-03-09

Print Preview

Print Preview (Short version)

Back To Search

Health And Youth Care Inspectorate

CERTIFICATE NUMBER: NL/H 26/2059602

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1) , (2)

Part 1

Issued following an inspection in accordance with
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Netherlands confirms the following:

The manufacturer: Zhejiang Huahai Pharmaceutical Co. Ltd.

Site address:

Xunqiao Linhai City, Taizhou, 317024, China

OMS Organisation Id. / OMS Location Id.: ORG-100011833 / LOC-100018698

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 8(2) of Regulation (EC) 726/2004.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2026-01-23 , it is considered that it complies with:

The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572. (3)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (https://eudragmdp.ema.europa.eu/). This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

__________________________________________________________________________________________________________________________

(1) The certificate referred to in paragraph Art. 111(5) of Directive 2001/83/ECis also applicable to importers.
(2) Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.
(3) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products

1 MANUFACTURING OPERATIONS

1.2 Non-sterile products

   1.2.1  Non-sterile products (processing operations for the following dosage forms)
           1.2.1.1  Capsules, hard shell
           1.2.1.13  Tablets

1.5 Packaging

   1.5.1  Primary Packaging
           1.5.1.1  Capsules, hard shell
           1.5.1.13  Tablets
   1.5.2  Secondary packaging

1.6 Quality control testing

1.6.2 Microbiological: non-sterility
1.6.3 Chemical/Physical

Clarifying remarks (for public users):

Buildings and workshops in scope are: building F1 with Workshop I, III and IV; building F2 with Workshop V. Products in scope are: Apixaban tablets, Aripiprazole tablets, Candesartan Cilexetil tablets, Candesartan Cilexetil Hydrochlorothiazide tablets, Donezepil Hydrochloride tablets, Empagliflozin capsules, Escitalopram film coated tablets, Gliclazide prolonged release tablets, Irbesartan film coated tablets, Lamotrigine tablets, Losartan Potassium film coated tablets, Pregabalin capsules, Quetiapine hemifumarate film coated tablets, Rivaroxaban film coated tablets, Rizatriptan Benzoate tablets, Telmisartan tablets, Telmisartan/Hydrochlorothiazide tablets, Valsartan film coated tablets, Valsartan/Hydrochlorothiazide tablets, Voriconazole tablets.

Withdrawal comments in English: Withdrawn to correct list of products to reference the correct form for some products. Same number was kept.

The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please click here to get list of NCA's.

For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI.

Documents issued by UK authorities up to and including 31 December 2020 remain available for consultation in EudraGMDP. However, they are no longer included or updated from 1 January 2021, with the exception of the documents pertaining to sites located in Northern Ireland.